Behavioral effects of the beta3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs?
A large body of evidence corroborates the notion that deficiencies of serotonergic system are likely involved in the pathogenesis of both depression and anxiety. Activation of beta(3) adrenoceptors has been shown to increase brain tryptophan content suggesting an elevation of brain serotonin (5HT) synthesis. SR58611A is a selective beta(3) adrenergic agent possessing a profile of antidepressant activity in routine rodents' experimental models of depression. The present study was undertaken to evaluate in rodents the antidepressant properties of SR58611A and to assess its putative anxiolytic value in experimental models of depression and anxiety. Compared to the control group, SR58611A (0.1, 1, 5 or 10 mg/kg) caused a dose-dependent reduction in immobility of Wistar male rats in the forced swim test. The maximum dose appeared to be equivalent to an effective dose of clomipramine (50 mg/kg). In addition, acute injection of SR58611A induced in rats a dose-dependent decrease in grooming response to a novel environment (novelty-induced grooming test). For any dose, the effect was lower than that of diazepam (1 mg/kg). Chronic treatment with SR58611A resulted also in an increased social interaction time in the social interaction test without affecting motor activity of rats. Furthermore, similarly to diazepam a chronic treatment with the highest doses of SR58611A was followed by increased exploratory behavior in Swiss male mice exposed to the elevated plus maze test. These effects are mediated by beta(3) adrenoceptors since i.p. pretreatment with the selective beta(3) adrenoceptor antagonist SR59230A (5 mg/kg) blocked the effects of SR58611A. Finally, also the 5HT antagonist methysergide (2 mg/kg) prevented the antidepressant and anxiolytic-like activity of SR58611A indicating that 5HT transmission is strictly involved in its action.
Consoli
Daniele
D
Department of Experimental and Clinical Pharmacology, Faculty of Medicine, University of Catania, Italy.
Leggio
Gian Marco
GM
Mazzola
Carmen
C
Micale
Vincenzo
V
Drago
Filippo
F
D058667:Adrenergic beta-3 Receptor Agonists; D058673:Adrenergic beta-3 Receptor Antagonists; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D000704:Analysis of Variance; D000818:Animals; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000494:pharmacology; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000494:pharmacology; D001007:Anxiety / Q000503:physiopathology / Q000517:prevention & control; D001522:Behavior, Animal / Q000187:drug effects*; D002997:Clomipramine / Q000008:administration & dosage / Q000494:pharmacology; D003863:Depression / Q000503:physiopathology / Q000517:prevention & control; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006120:Grooming / Q000187:drug effects; D007274:Injections, Intraperitoneal; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D008784:Methysergide / Q000008:administration & dosage / Q000494:pharmacology; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D011412:Propanolamines / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D022702:Receptors, Adrenergic, beta-3 / Q000502:physiology; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D013550:Swimming; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000494:pharmacology*
C097869:3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate; D058667:Adrenergic beta-3 Receptor Agonists; D058673:Adrenergic beta-3 Receptor Antagonists; D000319:Adrenergic beta-Antagonists; D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D011412:Propanolamines; D022702:Receptors, Adrenergic, beta-3; D012702:Serotonin Antagonists; D013764:Tetrahydronaphthalenes; D002997:Clomipramine; C076252:amibegron; D008784:Methysergide